Alector (ALEC) Akcija Цена

Alector Цена

NASDAQ·ZATVORENO
2,34
​
Tržište je zatvoreno

U poslednjih 9 godina prihod Alector rastao je 54,6 % godišnje i dostigao 21,05 М USD. Za Alector neto marža od -679,2 % je pala u odnosu na -13,5 % pre nekoliko godina. Konsenzusna 12-mesečna ciljana cena za Alector je 2,00 USD, oko ispod kurs za 14,3 %. Od 13 analitičara 8 preporučuje kupovinu — ukupni konsenzus je Kupi.

Cena akcije Alector

Pristupite ovim podacima preko Eulerpool API-ja

100.000 zahteva/mes. besplatno · bez kartice

Alector poslovni model i analiza akcije

Alector Inc. je biotehnološka kompanija osnovana 2013. godine. Ključna kompetencija kompanije je razvoj ciljanih terapija za prethodno neizlečive neurodegenerativne bolesti. Kompanija se nalazi u Južnoj San Francisku, u Kaliforniji, a osnovala ju je grupa uglednih naučnika. Osnivači su imali za cilj da razviju inovativne pristupe lečenju Alchajmerove i drugih neurodegenerativnih bolesti, inspirišući se procesima imunološkog sistema. Alector ima jedinstven poslovni model zasnovan na identifikaciji antitela za borbu protiv neurodegeneracije. Kompanija usko sarađuje sa akademskim institucijama, farmaceutskim partnerima i kliničarima kako bi razvila potencijalne lekove koji ciljaju različite aspekte ovih ozbiljnih bolesti. Alector je razvio platformsku tehnologiju pod nazivom "Lead-Selective Integrated Discovery Platform" (LSP) koja ga izdvaja. Ova platforma je sposobna da identifikuje specifična antitela koja mogu pomoći u inhibiciji mehanizama bolesti kod neurodegenerativnih poremećaja. Alector ima nekoliko proizvoda u različitim fazama razvoja. Obećavajući lek, AL001, trenutno je u fazi 1b/2a kliničkog razvoja za lečenje frontotemporalne demencije (FTD) i amiotrofne lateralne skleroze (ALS). Cilj ovog leka je sprečavanje prekomerne aktivacije imunološkog sistema u mozgu, što može doprineti simptomima bolesti. Kompanija takođe radi na drugom leku, AL002, koji cilja Alchajmerovu bolest. On je još uvek u prekliničkoj fazi razvoja. Alector je takođe stupio u partnerstvo sa kompanijom AbbVie Inc. (NYSE: ABBV) radi razvoja terapija na bazi antitela za Alchajmerovu bolest i druge neurološke poremećaje. Pored razvoja potencijalnih lekova, Alector sarađuje i sa drugim kompanijama kako bi učinila svoju tehnološku platformu dostupnom za druge industrije. Godine 2019, kompanija je potpisala sporazum sa GlaxoSmithKline plc (NYSE: GSK), kojim je GlaxoSmithKline-u omogućen pristup LSP platformi. Ukratko, Alector Inc. je vodeća biotehnološka kompanija specijalizovana za razvoj terapija na bazi antitela za neurodegenerativne bolesti. Uz inovativne tehnološke platforme i partnerstva sa drugim kompanijama, Alector teži stvaranju novih opcija lečenja za neizlečive bolesti poput Alchajmerove i ALS.

Često postavljana pitanja o akciji Alector

Alector Inc's business model focuses on utilizing its expertise in immunology and neurodegenerative diseases to develop innovative therapies. The company aims to harness the power of the immune system to target dysfunctional pathways and address the underlying causes of diseases like Alzheimer's and Parkinson's. Alector Inc leverages its proprietary immuno-neurology platform to identify potential therapeutic targets and develop antibodies that modulate the immune system's response. Through strategic collaborations and clinical trials, Alector Inc aims to advance transformative treatments and improve the lives of patients suffering from neurodegenerative disorders.

Alector Inc is primarily active in the biotechnology industry.

Alector Inc's main competitors in the market include Biogen Inc, Eli Lilly and Company, and Denali Therapeutics Inc.

Alector Inc is a biotechnology company founded in 2013 and is headquartered in South San Francisco, California. The company was established with a mission to develop innovative therapies to combat neurodegenerative diseases, including Alzheimer's disease and frontotemporal dementia. Alector focuses on harnessing the power of the immune system to target and eliminate disease-causing proteins, with the aim of slowing down or halting disease progression. Over the years, Alector has made significant advancements in its research and development, forging strategic partnerships and collaborations to drive the development of potential breakthrough treatments. Alector Inc remains committed to making a positive impact on patients' lives by addressing the urgent needs in neurological diseases.

Alector Inc has achieved significant milestones in its journey. The company has successfully advanced its proprietary immuno-neurology platform, focusing on developing transformative therapies for neurodegenerative diseases. A key achievement includes progressing its lead product candidates, AL002 and AL003, into clinical trials, demonstrating promising results and potential therapeutic benefits. Alector Inc has also secured strategic collaborations and partnerships with renowned pharmaceutical companies, enabling further research and development opportunities. These milestones highlight the company's dedication to innovative solutions in addressing critical unmet needs in the field of neurodegenerative disorders. Alector Inc's continued progress positions it as a leading player in the biotechnology industry, with a strong focus on improving patient outcomes.

Alector Inc is primarily present in the United States.

Alector Inc represents values of innovation, collaboration, and dedication to finding novel therapeutic treatments for neurodegenerative disorders. With a mission to improve the lives of patients, the company focuses on developing immune-modulatory therapies to target the root causes of diseases like Alzheimer's and Parkinson's. Alector Inc's corporate philosophy prioritizes scientific excellence, cutting-edge research, and a patient-centric approach. By harnessing the power of the immune system, the company aims to transform the treatment landscape and provide hope to individuals and families affected by neurodegenerative diseases. Alector Inc's commitment to scientific advancements and addressing unmet medical needs drives its mission to make a lasting impact in the field.

Analitičari trenutno postavljaju prosečnu ciljanu cenu 2,00 USD za akciju Alector (medijana: 2,00 USD), što znači -13,0 % u odnosu na poslednju cenu. Konsenzus se zasniva na 13 ocena.

13 analitičara trenutno ocenjuje akciju Alector: 8 preporučuje kupovinu, 3 držanje i 2 prodaju. Za 2026 analitičari očekuju da Alector ostvari prihod 221,89 М USD i zaradu po akciji 0,95 USD.

Po trenutnom kursu akcija Alector kotira 2,13 EUR (2,34 USD).

Akcija Alector (ALEC) kotira na 4 berze, uključujući: NASDAQ (ALEC), Frankfurt (0Z2.F), München (0Z2.MU), Düsseldorf (0Z2.DU).

Alector Inc is an innovative biotechnology company specializing in the research, development, and marketing of drugs to combat neurodegenerative diseases such as Alzheimer's and Parkinson's. The company was founded in 2013 by four leading experts in the field of neurobiology and is headquartered in South San Francisco, California, USA. Alector's business model is focused on developing groundbreaking therapies and drugs in the field of neurodegeneration. The company has several divisions, including a research team, clinical development departments, and a marketing and sales department. Alector's research team is involved in the identification and characterization of target proteins and mechanisms that are involved in the onset and progression of neurodegenerative diseases. The company uses an innovative, data-driven approach to understand the biological basis of these diseases and develop new targeted therapeutics. Alectron has developed a proprietary platform technology called "Immune Modulation Technology (IMT)", which utilizes the immune system in a unique way. IMT aims to modulate the activity of certain immune cells, called monocytes and macrophages. These cells are known to have the ability to eliminate pathogenic germs and abnormal proteins that can trigger neurodegenerative processes. However, in some cases, monocytes and macrophages themselves can produce harmful molecules and impair the body's defense mechanism against neurodegenerative diseases. Alector's approach is to selectively manipulate the activity of these cells and help them unleash their protective effect against neuropsychiatric disorders. Alector has conducted several clinical studies, including Phase 1 and Phase 2 studies with antibody products targeting neurodegenerative diseases. Currently, Alector is focusing on two core technologies. One is the so-called "Progranulin Receptor" (PGRN), which is attributed with significant therapeutic potential. The other is a model system called MET, which is also associated with neurodegenerative diseases. The company has also entered into several strategic partnerships with renowned pharmaceutical and technology companies to strengthen its portfolio of neurodegenerative therapeutics and its market position. These partnerships include collaborations with Biogen Inc. and AbbVie Inc. In summary, Alector aims to achieve a leading position in the market for neuropsychiatric diseases and deliver groundbreaking therapies for patients suffering from these often deadly and highly threatening diseases. It is based on the belief that an innovative approach combined with advanced technology and strategic partnerships offers the opportunity to have a positive impact on society and the health of millions of people worldwide.

očekivana prihod od Alector je 221,89 М USD. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.

očekivana dobit od Alector je 97,58 М USD. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.

Odnos cene i zarade (KGV) za Alector je trenutno 2,46. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije Alector.

Odnos cene i prihoda (KUV) za Alector je trenutno 1,08. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju Alector.

Eulpool score kvaliteta za Alector je 2/10.

ISIN za Alector je US0144421072. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.

WKN za Alector je A2PCBM. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.

Ticker za Alector je ALEC. Simbol tikera se koristi za trgovinu akcijama Alector na berzanskom tržištu.

Фер вредностTerminal
2,10 USD
Над-/ПодцењеностTerminal
Адекватно вредна
Сектор
Индустрија
Биотехнологија
Број акција
Запослени
Приход по запосленом
204.320,39 USD
Раст прихода Ø5 година
Раст EBIT Ø5 година
Раст нето добити Ø5 година
Веб сајт alector.com
Валута
USD
Јавна понуда
7. феб 2019.
ISIN
US0144421072
CUSIP
014442107
SEDOL
BJ4LDC4
Тржишна капитализација
254,87 М USDMicro Cap
Опсег од 52 недеље
AAQS
2 / 10
PEG
—
P/E однос
P/Ee 2026
2,61
P/Ee 2027
-3,27
P/Ee 2028
-3,31
P/Ee 2029
-3,09
P/Ee 2030
-3,55
P/Se
1,08
EV/EBIT
—
P/B однос
8,32
ROE (Поврат на капитал)
ROA (Поврат на имовину)
ROCE (Поврат на ангажовани капитал)
ROIC (Поврат на уложени капитал)
-213,70 %
Zadnje ažurirano 21. нов 2026. 12:10

Alector Тикер

DISELORF · 0Z2.DUFRANKFURT · 0Z2.FMINHEN · 0Z2.MUNASDAQ · ALEC

Alector FIGI

ALEC:US · BBG00N0PL198ALEC:UA · BBG00N0PL1B5ALEC:UC · BBG00N0PL1C4ALEC:UN · BBG00N0PL1F1ALEC:UP · BBG00N0PL1G0ALEC:UB · BBG00N0PL1J7ALEC:UM · BBG00N0PL1L4ALEC:UX · BBG00N0PL1M3ALEC:UD · BBG00N0PL1S7ALEC:UW · BBG00N0PL1V3ALEC:UF · BBG00N0PL1W2ALEC:VY · BBG00N0PL1X1